Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 33

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Pseudomonas aeruginosa Vaccine Development: Lessons, Challenges, and Future Innovations

Santamarina-Fernández, Rebeca, Fuentes-Valverde, Víctor, Silva-Rodríguez, Alis, García, Patricia, Moscoso, Miriam, Bou, Germán·2025·International Journal of Molecular Sciences

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen with a multidrug-resistant profile that has become a critical threat to global public health. It is one of the main causes of severe nosocomial infections, including ventilator-associated pneumonia, chronic infections in patients with cystic fibrosis, and bloodstream infections in immunosuppressed individuals. Development of vaccines against P. aeruginosa is a major challenge owing to the high capacity of this bacterium to form biofilms, its wide arsenal of virulence factors (including secretion systems, lipopolysaccharides, and outer membrane proteins), and its ability to evade the host immune system. This review provides a comprehensive historical overview of vaccine development efforts targeting this pathogen, ranging from early attempts in the 1970s to recent advancements, including vaccines based on novel proteins and emerging technologies such as nanoparticles and synthetic conjugates. Despite numerous promising preclinical developments, very few candidates have progressed to clinical trials, and none have achieved final approval. This panorama highlights the significant scientific efforts undertaken and the inherent complexity of successfully developing an effective vaccine against P. aeruginosa.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms26052012

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 229

  1. Murray, 2022, Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis, Lancet, 399, 629, 10.1016/S0140-6736(21)02724-0 · DOI · Paper page
  2. Pirnay, J.-P., Bilocq, F., Pot, B., Cornelis, P., Zizi, M., Van Eldere, J., Deschaght, P., Vaneechoutte, M., Jennes, S., and Pitt, T. (2009). Pseudomonas aeruginosa Population Structure Revisited. PLoS ONE, 4. · DOI · Paper page
  3. Abner, 2020, Antimicrobial-Resistant Pathogens Associated with Adult Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network, 2015–2017, Infect. Control Hosp. Epidemiol., 41, 1
  4. Raoofi, S., Pashazadeh Kan, F., Rafiei, S., Hosseinipalangi, Z., Noorani Mejareh, Z., Khani, S., Abdollahi, B., Seyghalani Talab, F., Sanaei, M., and Zarabi, F. (2023). Global Prevalence of Nosocomial Infection: A Systematic Review and Meta-Analysis. PLoS ONE, 18. · doi:10.1371/journal.pone.0274248
  5. Irek, E.O., Amupitan, A.A., Obadare, T.O., and Aboderin, A.O. (2018). A Systematic Review of Healthcare-Associated Infections in Africa: An Antimicrobial Resistance Perspective. Afr. J. Lab. Med., 7. · DOI
  6. Killough, M., Rodgers, A.M., and Ingram, R.J. (2022). Pseudomonas aeruginosa: Recent Advances in Vaccine Development. Vaccines, 10. · DOI · Paper page
  7. Hortal, J., Muñoz, P., Cuerpo, G., Litvan, H., Rosseel, P.M., and Bouza, E. (2009). Ventilator-Associated Pneumonia in Patients Undergoing Major Heart Surgery: An Incidence Study in Europe. Crit. Care, 13. · DOI
  8. Berra, 2010, Pseudomonas aeruginosa: Acute Lung Injury or Ventilator-Associated Pneumonia?, Minerva Anestesiol., 76, 824
  9. Chou, 2019, Recommendations and Guidelines for the Treatment of Pneumonia in Taiwan, J. Microbiol. Immunol. Infect., 52, 172, 10.1016/j.jmii.2018.11.004 · DOI
  10. Jean, S.-S., Chang, Y.-C., Lin, W.-C., Lee, W.-S., Hsueh, P.-R., and Hsu, C.-W. (2020). Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia. J. Clin. Med., 9. · DOI
  11. Luyt, 2018, Microbial Cause of ICU-Acquired Pneumonia: Hospital-Acquired Pneumonia versus Ventilator-Associated Pneumonia, Curr. Opin. Crit. Care, 24, 332, 10.1097/MCC.0000000000000526 · DOI
  12. Anwar, 2024, Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies, Adv. Respir. Med., 92, 263, 10.3390/arm92040026 · DOI
  13. Prince, 2007, Opportunistic Infections in Lung Disease: Pseudomonas Infections in Cystic Fibrosis, Curr. Opin. Pharmacol., 7, 244, 10.1016/j.coph.2006.12.005 · DOI · Paper page
  14. Jarych, D., Augustynowicz-Kopec, E., Iwanska, A., Parniewski, P., and Majchrzak, M. (2021). Molecular Analysis of Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients. Sci. Rep., 11. · doi:10.1038/s41598-021-95034-2
  15. Strateva, 2011, Contribution of an Arsenal of Virulence Factors to Pathogenesis of Pseudomonas aeruginosa Infections, Ann. Microbiol., 61, 717, 10.1007/s13213-011-0273-y · DOI · Paper page
  16. Koch, 2012, The Multiple Signaling Systems Regulating Virulence in Pseudomonas aeruginosa, Microbiol. Mol. Biol. Rev., 76, 46, 10.1128/MMBR.05007-11 · DOI · Paper page
  17. Balasubramanian, 2013, A Dynamic and Intricate Regulatory Network Determines Pseudomonas aeruginosa Virulence, Nucleic Acids Res., 41, 1, 10.1093/nar/gks1039 · DOI · Paper page
  18. Jurado-Martín, I., Sainz-Mejías, M., and McClean, S. (2021). Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int. J. Mol. Sci., 22. · DOI · Paper page
  19. Huszczynski, S.M., Lam, J.S., and Khursigara, C.M. (2019). The Role of Pseudomonas aeruginosa Lipopolysaccharide in Bacterial Pathogenesis and Physiology. Pathogens, 9. · DOI · Paper page
  20. Lee, 2017, Pseudomonas aeruginosa Biofilm, a Programmed Bacterial Life for Fitness, J. Microbiol. Biotechnol., 27, 1053, 10.4014/jmb.1611.11056 · DOI · Paper page
  21. Mann, 2012, Pseudomonas Biofilm Matrix Composition and Niche Biology, FEMS Microbiol. Rev., 36, 893, 10.1111/j.1574-6976.2011.00322.x · DOI · Paper page
  22. Hoffman, 2005, Aminoglycoside Antibiotics Induce Bacterial Biofilm Formation, Nature, 436, 1171, 10.1038/nature03912 · DOI · Paper page
  23. Goltermann, L., and Tolker-Nielsen, T. (2017). Importance of the Exopolysaccharide Matrix in Antimicrobial Tolerance of Pseudomonas aeruginosa Aggregates. Antimicrob. Agents Chemother., 61. · DOI
  24. Williams McMackin, E.A., Djapgne, L., Corley, J.M., and Yahr, T.L. (2019). Fitting Pieces into the Puzzle of Pseudomonas aeruginosa Type III Secretion System Gene Expression. J. Bacteriol., 201. · DOI
  25. Hauser, 2009, The Type III Secretion System of Pseudomonas aeruginosa: Infection by Injection, Nat. Rev. Microbiol., 7, 654, 10.1038/nrmicro2199 · DOI · Paper page
  26. Sana, T.G., Berni, B., and Bleves, S. (2016). The T6SSs of Pseudomonas aeruginosa Strain PAO1 and Their Effectors: Beyond Bacterial-Cell Targeting. Front. Cell Infect. Microbiol., 6. · DOI · Paper page
  27. Schwarzer, C., Fischer, H., and Machen, T.E. (2016). Chemotaxis and Binding of Pseudomonas aeruginosa to Scratch-Wounded Human Cystic Fibrosis Airway Epithelial Cells. PLoS ONE, 11. · DOI
  28. Jacobsen, 2020, Structure and Function of Minor Pilins of Type IV Pili, Med. Microbiol. Immunol., 209, 301, 10.1007/s00430-019-00642-5 · DOI
  29. Perraud, 2020, Phenotypic Adaption of Pseudomonas aeruginosa by Hacking Siderophores Produced by Other Microorganisms, Mol. Cell Proteom., 19, 589, 10.1074/mcp.RA119.001829 · DOI
  30. Paola, 2012, Visión panorámica del sistema inmune, Rev. Medica Clin. Las Condes, 23, 446
  31. Sainz-Mejías, M., Jurado-Martín, I., and McClean, S. (2020). Understanding Pseudomonas aeruginosa–Host Interactions: The Ongoing Quest for an Efficacious Vaccine. Cells, 9. · DOI
  32. Lavoie, 2011, Innate Immune Responses to Pseudomonas aeruginosa Infection, Microbes Infect., 13, 1133, 10.1016/j.micinf.2011.07.011 · DOI · Paper page
  33. Morris, A.E., Liggitt, H.D., Hawn, T.R., and Skerrett, S.J. (2009). Role of Toll-like Receptor 5 in the Innate Immune Response to Acute P. aeruginosa Pneumonia. Am. J. Physiol.-Lung Cell. Mol. Physiol., 297. · DOI
  34. Lee, 2003, Phagocytosis by Neutrophils, Microbes Infect., 5, 1299, 10.1016/j.micinf.2003.09.014 · DOI · Paper page
  35. Jouault, A., Saliba, A.M., and Touqui, L. (2022). Modulation of the Immune Response by the Pseudomonas aeruginosa Type-III Secretion System. Front. Cell Infect. Microbiol., 12. · DOI
  36. Moser, C., Jensen, P.Ø., Thomsen, K., Kolpen, M., Rybtke, M., Lauland, A.S., Trøstrup, H., and Tolker-Nielsen, T. (2021). Immune Responses to Pseudomonas aeruginosa Biofilm Infections. Front. Immunol., 12. · DOI · Paper page
  37. Hastings, C.J., Himmler, G.E., Patel, A., and Marques, C.N.H. (2023). Immune Response Modulation by Pseudomonas aeruginosa Persister Cells. mBio, 14. · DOI
  38. Mak, T.W., Saunders, M.E., and Jett, B.D. (2014). Chapter 12—Mucosal and Cutaneous Immunity. Primer to the Immune Response, Academic Cell. [2nd ed.].
  39. Bayes, 2016, Interleukin-17 Is Required for Control of Chronic Lung Infection Caused by Pseudomonas aeruginosa, Infect. Immun., 84, 3507, 10.1128/IAI.00717-16 · DOI
  40. Mak, T.W., Saunders, M.E., and Jett, B.D. (2014). Chapter 9—T Cell Development, Activation and Effector Functions. Primer to the Immune Response, Academic Cell. [2nd ed.].
  41. Ding, F., Han, L., Fu, Q., Fan, X., Tang, R., Lv, C., Xue, Y., Tian, X., and Zhang, M. (2022). IL-17 Aggravates Pseudomonas aeruginosa Airway Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Front. Immunol., 12. · DOI
  42. Wonnenberg, 2016, The Role of IL-1β in Pseudomonas aeruginosa in Lung Infection, Cell Tissue Res., 364, 225, 10.1007/s00441-016-2387-9 · DOI
  43. Lovewell, R.R., Patankar, Y.R., and Berwin, B. (2014). Mechanisms of Phagocytosis and Host Clearance of Pseudomonas aeruginosa. Am. J. Physiol.-Lung Cell. Mol. Physiol., 306. · DOI · Paper page
  44. Malhotra, S., Don Hayes, J., and Wozniak, D.J. (2019). Cystic Fibrosis and Pseudomonas aeruginosa: The Host-Microbe Interface. Clin. Microbiol. Rev., 32. · DOI · Paper page
  45. Hajj Hussein, I., Chams, N., Chams, S., El Sayegh, S., Badran, R., Raad, M., Gerges-Geagea, A., Leone, A., and Jurjus, A. (2015). Vaccines Through Centuries: Major Cornerstones of Global Health. Front. Public Health, 3. · DOI · Paper page
  46. Corbett, 2020, SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness, Nature, 586, 567, 10.1038/s41586-020-2622-0 · DOI · Paper page
  47. Mak, T.W., Saunders, M.E., and Jett, B.D. (2014). Chapter 14—Vaccination. Primer to the Immune Response, Academic Cell. [2nd ed.].
  48. Kamei, 2011, Mucosal Vaccination with a Multivalent, Live-Attenuated Vaccine Induces Multifactorial Immunity against Pseudomonas aeruginosa Acute Lung Infection, Infect. Immun., 79, 1289, 10.1128/IAI.01139-10 · DOI
  49. Fuentes-Valverde, V., García, P., Moscoso, M., and Bou, G. (2022). Double Auxotrophy to Improve the Safety of a Live Anti-Pseudomonas aeruginosa Vaccine. Vaccines, 10. · DOI
  50. Cabral, M.P., Correia, A., Vilanova, M., Gärtner, F., Moscoso, M., García, P., Vallejo, J.A., Pérez, A., Francisco-Tomé, M., and Fuentes-Valverde, V. (2020). A Live Auxotrophic Vaccine Confers Mucosal Immunity and Protection against Lethal Pneumonia Caused by Pseudomonas aeruginosa. PLoS Pathog., 16. · DOI
  51. Priebe, 2003, Protection against Fatal Pseudomonas aeruginosa Pneumonia in Mice after Nasal Immunization with a Live, Attenuated aroA Deletion Mutant, Infect. Immun., 71, 1453, 10.1128/IAI.71.3.1453-1461.2003 · DOI
  52. Priebe, G.P., Brinig, M.M., Hatano, K., Grout, M., Coleman, F.T., Pier, G.B., and Goldberg, J.B. (2002). Construction and Characterization of a Live, Attenuated aroA Deletion Mutant of Pseudomonas aeruginosa as a Candidate Intranasal Vaccine. Infect. Immun., 70. · doi:10.1128/iai.70.3.1507-1517.2002
  53. Priebe, 2008, IL-17 Is a Critical Component of Vaccine-Induced Protection against Lung Infection by LPS-Heterologous Strains of Pseudomonas aeruginosa, J. Immunol., 181, 4965, 10.4049/jimmunol.181.7.4965 · DOI
  54. Cabral, M.P., García, P., Beceiro, A., Rumbo, C., Pérez, A., Moscoso, M., and Bou, G. (2017). Design of Live Attenuated Bacterial Vaccines Based on D-Glutamate Auxotrophy. Nat. Commun., 8. · DOI
  55. Pigula, M., Lai, Y.-C., Koh, M., Diercks, C.S., Rogers, T.F., Dik, D.A., and Schultz, P.G. (2024). An Unnatural Amino Acid Dependent, Conditional Pseudomonas Vaccine Prevents Bacterial Infection. Nat. Commun., 15. · doi:10.1038/s41467-024-50843-7
  56. DiGiandomenico, 2004, Oral Vaccination of BALB/c Mice with Salmonella enterica Serovar Typhimurium Expressing Pseudomonas aeruginosa O Antigen Promotes Increased Survival in an Acute Fatal Pneumonia Model, Infect. Immun., 72, 7012, 10.1128/IAI.72.12.7012-7021.2004 · doi:10.1128/iai.72.12.7012-7021.2004
  57. DiGiandomenico, 2007, Intranasal Immunization with Heterologously Expressed Polysaccharide Protects against Multiple Pseudomonas aeruginosa Infections, Proc. Natl. Acad. Sci. USA, 104, 4624, 10.1073/pnas.0608657104 · doi:10.1073/pnas.0608657104
  58. Scarff, 2008, Vaccination against Pseudomonas aeruginosa Pneumonia in Immunocompromised Mice, Clin. Vaccine Immunol., 15, 367, 10.1128/CVI.00419-07 · doi:10.1128/cvi.00419-07
  59. Moustafa, D.A., DiGiandomenico, A., Raghuram, V., Schulman, M., Scarff, J.M., Michael R Davis, J., Varga, J.J., Dean, C.R., and Goldberg, J.B. (2023). Efficacy of a Pseudomonas aeruginosa Serogroup O9 Vaccine. Infect. Immun., 91. · DOI
  60. Bridge, 2016, Heterologous Pseudomonas aeruginosa O-Antigen Delivery Using a Salmonella enterica Serovar Typhimurium wecA Mutant Strain, Int. J. Med. Microbiol., 306, 529, 10.1016/j.ijmm.2016.06.005 · doi:10.1016/j.ijmm.2016.06.005
  61. Dubensky, 2012, Killed but Metabolically Active Vaccines, Curr. Opin. Biotechnol., 23, 917, 10.1016/j.copbio.2012.04.005 · DOI
  62. Meynet, 2018, Killed but Metabolically Active Pseudomonas aeruginosa-Based Vaccine Induces Protective Humoral- and Cell-Mediated Immunity against Pseudomonas aeruginosa Pulmonary Infections, Vaccine, 36, 1893, 10.1016/j.vaccine.2018.02.040 · doi:10.1016/j.vaccine.2018.02.040
  63. Cripps, 1994, Mucosal and Systemic Immunizations with Killed Pseudomonas aeruginosa Protect against Acute Respiratory Infection in Rats, Infect. Immun., 62, 1427, 10.1128/iai.62.4.1427-1436.1994 · doi:10.1128/iai.62.4.1427-1436.1994
  64. Cripps, 2006, Safety and Immunogenicity of an Oral Inactivated Whole-Cell Pseudomonas aeruginosa Vaccine Administered to Healthy Human Subjects, Infect. Immun., 74, 968, 10.1128/IAI.74.2.968-974.2006 · doi:10.1128/iai.74.2.968-974.2006
  65. Rodgers, 2018, Design and Characterisation of a Dissolving Microneedle Patch for Intradermal Vaccination with Heat-Inactivated Bacteria: A Proof of Concept Study, Int. J. Pharm., 549, 87, 10.1016/j.ijpharm.2018.07.049 · doi:10.1016/j.ijpharm.2018.07.049
  66. Blackwood, C.B., Sen-Kilic, E., Boehm, D.T., Hall, J.M., Varney, M.E., Wong, T.Y., Bradford, S.D., Bevere, J.R., Witt, W.T., and Damron, F.H. (2020). Innate and Adaptive Immune Responses against Bordetella pertussis and Pseudomonas aeruginosa in a Murine Model of Mucosal Vaccination against Respiratory Infection. Vaccines, 8. · DOI
  67. Sen-Kilic, E., Blackwood, C.B., Huckaby, A.B., Horspool, A.M., Weaver, K.L., Malkowski, A.C., Witt, W.T., Bevere, J.R., Damron, F.H., and Barbier, M. (2021). Defining the Mechanistic Correlates of Protection Conferred by Whole-Cell Vaccination against Pseudomonas aeruginosa Acute Murine Pneumonia. Infect. Immun., 89. · DOI
  68. Fan, 2019, Hydrogen Peroxide-Inactivated Bacteria Induces Potent Humoral and Cellular Immune Responses and Releases Nucleic Acids, Int. Immunopharmacol., 69, 389, 10.1016/j.intimp.2019.01.055 · DOI
  69. Amara, A.A., Salem-Bekhit, M.M., and Alanazi, F.K. (2013). Sponge-Like: A New Protocol for Preparing Bacterial Ghosts. Sci. World J., 2013. · DOI
  70. Sheweita, S.A., Amara, A.A., Gamal, H., Ghazy, A.A., Hussein, A., and Bahey-El-Din, M. (2022). Bacterial Ghosts of Pseudomonas aeruginosa as a Promising Candidate Vaccine and Its Application in Diabetic Rats. Vaccines, 10. · doi:10.3390/vaccines10060910
  71. Jiang, 2023, An X-Ray Inactivated Vaccine against Pseudomonas aeruginosa Keratitis in Mice, Vaccine, 41, 4700, 10.1016/j.vaccine.2023.05.066 · doi:10.1016/j.vaccine.2023.05.066
  72. Fisher, 1969, New Immunotype Schema for Pseudomonas aeruginosa Based on Protective Antigens, J. Bacteriol., 98, 835, 10.1128/jb.98.2.835-836.1969 · DOI · Paper page
  73. Hanessian, 1971, Isolation and Characterization of Antigenic Components of a New Heptavalent Pseudomonas Vaccine, Nat. New Biol., 229, 209, 10.1038/newbio229209a0 · doi:10.1038/newbio229209a0
  74. Alexander, 1969, Prevention of Invasive Pseudomonas Infection in Burns with a New Vaccine, Arch. Surg., 99, 249, 10.1001/archsurg.1969.01340140121018 · doi:10.1001/archsurg.1969.01340140121018
  75. Alexander, 1970, Immunological Determinants of Pseudomonas Infections of Man Accompanying Severe Burn Injury, J. Trauma., 10, 565, 10.1097/00005373-197007000-00005 · doi:10.1097/00005373-197007000-00005
  76. Alexander, J.W., and Fisher, M.W. (1970). Vaccination for Pseudomonas aeruginosa. Am. J. Surg., 120. · doi:10.1016/s0002-9610(70)80019-8
  77. Alexander, 1971, Immunological Control of Pseudomonas Infection in Burn Patients: A Clinical Evaluation, Arch. Surg., 102, 31, 10.1001/archsurg.1971.01350010033008 · doi:10.1001/archsurg.1971.01350010033008
  78. Young, 1973, Pseudomonas aeruginosa Vaccine in Cancer Patients, Ann. Intern. Med., 79, 518, 10.7326/0003-4819-79-4-518 · doi:10.7326/0003-4819-79-4-518
  79. Pennington, 1975, Use of a Pseudomonas aeruginosa Vaccine in Pateints with Acute Leukemia and Cystic Fibrosis, Am. J. Med., 58, 629, 10.1016/0002-9343(75)90498-2 · doi:10.1016/0002-9343(75)90498-2
  80. Haghbin, 1973, Controlled Prospective Trial of Pseudomonas aeruginosa Vaccine in Children with Acute Leukemia, Cancer, 32, 761, 10.1002/1097-0142(197310)32:4<761::AID-CNCR2820320405>3.0.CO;2-H · doi:10.1002/1097-0142(197310)32:4<761::aid-cncr2820320405>3.0.co;2-h
  81. Pennington, 1974, Preliminary Investigations of Pseudomonas aeruginosa Vaccine in Patients with Leukemia and Cystic Fibrosis, J. Infect. Dis., 130, S159, 10.1093/infdis/130.Supplement.S159 · doi:10.1093/infdis/130.supplement.s159
  82. Miler, 1977, A New Polyvalent Pseudomonas Vaccine, J. Med. Microbiol., 10, 19, 10.1099/00222615-10-1-19 · doi:10.1099/00222615-10-1-19
  83. Roe, 1983, Immunization of Burned Patients against Pseudomonas aeruginosa Infection at Safdarjang Hospital, New Delhi, Rev. Infect. Dis., 5, S922, 10.1093/clinids/5.Supplement_5.S922 · doi:10.1093/clinids/5.supplement_5.s922
  84. Jones, 1976, A New Pseudomonas Vaccine: Preliminary Trial on Human Volunteers, Epidemiol. Infect., 76, 429
  85. Langford, 1984, Prospective, Controlled Study of a Polyvalent Pseudomonas Vaccine in Cystic Fibrosis—Three Year Results, Arch. Dis. Child., 59, 1131, 10.1136/adc.59.12.1131 · doi:10.1136/adc.59.12.1131
  86. Cryz, 1986, Pseudomonas aeruginosa Immunotype 5 Polysaccharide-Toxin A Conjugate Vaccine, Infect. Immun., 52, 161, 10.1128/iai.52.1.161-165.1986 · doi:10.1128/iai.52.1.161-165.1986
  87. Cryz, 1987, Safety and Immunogenicity of a Pseudomonas aeruginosa O-Polysaccharide Toxin A Conjugate Vaccine in Humans, J. Clin. Investig., 80, 51, 10.1172/JCI113062 · doi:10.1172/jci113062
  88. Schaad, 1991, Safety and Immunogenicity of Pseudomonas aeruginosa Conjugate A Vaccine in Cystic Fibrosis, Lancet, 338, 1236, 10.1016/0140-6736(91)92103-9 · doi:10.1016/0140-6736(91)92103-9
  89. Cryz, 1988, Immunization with a Pseudomonas aeruginosa Immunotype 5 O Polysaccharide-Toxin A Conjugate Vaccine: Effect of a Booster Dose on Antibody Levels in Humans, Infect. Immun., 56, 1829, 10.1128/iai.56.7.1829-1830.1988 · doi:10.1128/iai.56.7.1829-1830.1988
  90. 2010, Prevention of Pseudomonas aeruginosa Infection in Cystic Fibrosis Patients, Int. J. Med. Microbiol., 300, 573, 10.1016/j.ijmm.2010.08.010 · doi:10.1016/j.ijmm.2010.08.010
  91. Bahy, 2022, Preparation and Evaluation of a New Combined Conjugated Vaccine against Klebsiella pneumoniae and Pseudomonas aeruginosa, J. Appl. Microbiol., 133, 1543, 10.1111/jam.15646 · doi:10.1111/jam.15646
  92. Pier, 2003, Promises and Pitfalls of Pseudomonas aeruginosa Lipopolysaccharide as a Vaccine Antigen, Carbohydr. Res., 338, 2549, 10.1016/S0008-6215(03)00312-4 · doi:10.1016/s0008-6215(03)00312-4
  93. Hatano, 1994, Immunogenic and Antigenic Properties of a Heptavalent High-Molecular-Weight O-Polysaccharide Vaccine Derived from Pseudomonas aeruginosa, Infect. Immun., 62, 3608, 10.1128/iai.62.9.3608-3616.1994 · doi:10.1128/iai.62.9.3608-3616.1994
  94. Saylor, K., Gillam, F., Lohneis, T., and Zhang, C. (2020). Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy. Front. Immunol., 11. · DOI
  95. Tuon, F.F., Dantas, L.R., Suss, P.H., and Tasca Ribeiro, V.S. (2022). Pathogenesis of the Pseudomonas aeruginosa Biofilm: A Review. Pathogens, 11. · DOI · Paper page
  96. Pier, 1990, Protection against Mucoid Pseudomonas aeruginosa in Rodent Models of Endobronchial Infections, Science, 249, 537, 10.1126/science.2116663 · doi:10.1126/science.2116663
  97. Pier, 1994, Human Immune Response to Pseudomonas aeruginosa Mucoid Exopolysaccharide (Alginate) Vaccine, Infect. Immun., 62, 3972, 10.1128/iai.62.9.3972-3979.1994 · DOI
  98. Cryz, 1991, Synthesis and Characterization of a Pseudomonas aeruginosa Alginate-Toxin A Conjugate Vaccine, Infect. Immun., 59, 45, 10.1128/iai.59.1.45-50.1991 · doi:10.1128/iai.59.1.45-50.1991
  99. Theilacker, 2003, Construction and Characterization of a Pseudomonas aeruginosa Mucoid Exopolysaccharide-Alginate Conjugate Vaccine, Infect. Immun., 71, 3875, 10.1128/IAI.71.7.3875-3884.2003 · doi:10.1128/iai.71.7.3875-3884.2003
  100. Azimi, 2021, Immunization against Pseudomonas aeruginosa Using Alg-PLGA Nano-Vaccine, Iran. J. Basic. Med. Sci., 24, 476
  101. Afshari, H., Maleki, M., Hakimian, M., Tanha, R.A., and Salouti, M. (2021). Immunogenicity Evaluating of the SLNs-Alginate Conjugate against Pseudomonas aeruginosa. J. Immunol. Methods, 488. · doi:10.1016/j.jim.2020.112938
  102. Zhang, 2024, A Semisynthetic Oligomannuronic Acid-Based Glycoconjugate Vaccine against Pseudomonas aeruginosa, ACS Cent. Sci., 10, 1515, 10.1021/acscentsci.4c00387 · DOI
  103. Moyle, 2013, Modern Subunit Vaccines: Development, Components, and Research Opportunities, ChemMedChem, 8, 360, 10.1002/cmdc.201200487 · DOI · Paper page
  104. Finke, 1990, Protection against Experimental Pseudomonas aeruginosa Infection by Recombinant P. aeruginosa Lipoprotein I Expressed in Escherichia coli, Infect. Immun., 58, 2241, 10.1128/iai.58.7.2241-2244.1990 · DOI
  105. Parvaei, M., Habibi, M., Shahbazi, S., Babaluei, M., Farokhi, M., and Asadi Karam, M.R. (2024). Immunostimulatory Chimeric Protein Encapsulated in Gelatin Nanoparticles Elicits Protective Immunity against Pseudomonas aeruginosa Respiratory Tract Infection. Int. J. Biol. Macromol., 277. · DOI
  106. Robertson, 1990, Pseudomonas aeruginosa Outer Membrane Protein F Produced in Escherichia coli Retains Vaccine Efficacy, Curr. Microbiol., 20, 171, 10.1007/BF02091993 · DOI
  107. Gilleland, 1993, Vaccine Efficacies of Elastase, Exotoxin A, and Outer-Membrane Protein F in Preventing Chronic Pulmonary Infection by Pseudomonas aeruginosa in a Rat Model, J. Med. Microbiol., 38, 79, 10.1099/00222615-38-2-79 · doi:10.1099/00222615-38-2-79
  108. Peluso, L., de Luca, C., Bozza, S., Leonardi, A., Giovannini, G., Lavorgna, A., Rosa, G.D., Mascolo, M., Luna, L.O.D., and Catania, M.R. (2010). Protection against Pseudomonas aeruginosa Lung Infection in Mice by Recombinant OprF-Pulsed Dendritic Cell Immunization. BMC Microbiol., 10. · DOI
  109. Worgall, S., Krause, A., Rivara, M., Hee, K.-K., Vintayen, E.V., Hackett, N.R., Roelvink, P.W., Bruder, J.T., Wickham, T.J., and Kovesdi, I. (2005). Protection against P. aeruginosa with an Adenovirus Vector Containing an OprF Epitope in the Capsid. J. Clin. Investig., 115. · doi:10.1172/jci23135
  110. Krause, A., Whu, W.Z., Qiu, J., Wafadari, D., Hackett, N.R., Sharma, A., Crystal, R.G., and Worgall, S. (2013). RGD Capsid Modification Enhances Mucosal Protective Immunity of a Non-Human Primate Adenovirus Vector Expressing Pseudomonas aeruginosa OprF. Clin. Exp. Immunol., 173. · DOI
  111. Worgall, S., Krause, A., Qiu, J., Joh, J., Hackett, N.R., and Crystal, R.G. (2007). Protective Immunity to Pseudomonas aeruginosa Induced with a Capsid-Modified Adenovirus Expressing P. aeruginosa OprF. J. Virol., 81. · DOI
  112. Krause, A., Whu, W.Z., Xu, Y., Joh, J., Crystal, R.G., and Worgall, S. (2011). Protective Anti-Pseudomonas aeruginosa Humoral and Cellular Mucosal Immunity by AdC7-Mediated Expression of the P. aeruginosa Protein OprF. Vaccine, 29. · DOI
  113. Bahey-El-Din, M., Mohamed, S.A., Sheweita, S.A., Haroun, M., and Zaghloul, T.I. (2020). Recombinant N-Terminal Outer Membrane Porin (OprF) of Pseudomonas aeruginosa Is a Promising Vaccine Candidate against Both P. aeruginosa and Some Strains of Acinetobacter baumannii. Int. J. Med. Microbiol., 310. · DOI
  114. Mayeux, G., Gayet, L., Liguori, L., Odier, M., Martin, D.K., Cortès, S., Schaack, B., and Lenormand, J.-L. (2021). Cell-Free Expression of the Outer Membrane Protein OprF of Pseudomonas aeruginosa for Vaccine Purposes. Life Sci. Alliance, 4. · DOI
  115. Thanvi, R., Nada, S., Dissanayake, R., Vartak, A., Sebilleau, C.O., Alom, N.-E., Prestwich, E.G., Wall, K.A., and Sucheck, S.J. (2023). Synthesis and Evaluation of a Self-Adjuvanting Pseudomonal Vaccine Based on Major Outer Membrane Porin OprF Epitopes Formulated with Low-Toxicity QS-21-Containing Liposomes. Bioconjugate Chem., 34. · DOI
  116. Gomi, 2017, Post-Exposure Immunization by Capsid-Modified AdC7 Vector Expressing Pseudomonas aeruginosa OprF Clears P. Aeruginosa Respiratory Infection, Vaccine, 35, 7174, 10.1016/j.vaccine.2017.10.078 · doi:10.1016/j.vaccine.2017.10.078
  117. Chen, 1999, Recombinant Protein Composed of Pseudomonas Exotoxin A, Outer Membrane Proteins I and F as Vaccine against P. aeruginosa Infection, Appl. Microbiol. Biotechnol., 52, 524, 10.1007/s002530051555 · doi:10.1007/s002530051555
  118. Lee, J.W., Parlane, N.A., Wedlock, D.N., and Rehm, B.H.A. (2017). Bioengineering a Bacterial Pathogen to Assemble Its Own Particulate Vaccine Capable of Inducing Cellular Immunity. Sci. Rep., 7. · DOI
  119. Zhang, 2015, Salmonella Typhimurium Strain Expressing OprF-OprI Protects Mice against Fatal Infection by Pseudomonas aeruginosa, Microbiol. Immunol., 59, 533, 10.1111/1348-0421.12291 · doi:10.1111/1348-0421.12291
  120. Cui, 2015, Mannose-Modified Chitosan Microspheres Enhance OprF-OprI-Mediated Protection of Mice against Pseudomonas aeruginosa Infection via Induction of Mucosal Immunity, Appl. Microbiol. Biotechnol., 99, 667, 10.1007/s00253-014-6147-z · doi:10.1007/s00253-014-6147-z
  121. Hassan, 2018, Immunization with Outer Membrane Proteins (OprF and OprI) and Flagellin B Protects Mice from Pulmonary Infection with Mucoid and Nonmucoid Pseudomonas aeruginosa, J. Microbiol. Immunol. Infect., 51, 312, 10.1016/j.jmii.2016.08.014 · doi:10.1016/j.jmii.2016.08.014
  122. Jing, 2020, Oligomerization of IC43 Resulted in Improved Immunogenicity and Protective Efficacy against Pseudomonas aeruginosa Lung Infection, Int. J. Biol. Macromol., 159, 174, 10.1016/j.ijbiomac.2020.05.057 · DOI
  123. Westritschnig, 2014, A Randomized, Placebo-Controlled Phase I Study Assessing the Safety and Immunogenicity of a Pseudomonas aeruginosa Hybrid Outer Membrane Protein OprF/I Vaccine (IC43) in Healthy Volunteers, Hum. Vaccines Immunother., 10, 170, 10.4161/hv.26565 · DOI
  124. Mansouri, 1999, Safety and Immunogenicity of a Pseudomonas aeruginosa Hybrid Outer Membrane Protein F-I Vaccine in Human Volunteers, Infect. Immun., 67, 1461, 10.1128/IAI.67.3.1461-1470.1999 · DOI
  125. Mansouri, 2003, Clinical Study to Assess the Immunogenicity and Safety of a Recombinant Pseudomonas aeruginosa OprF-OprI Vaccine in Burn Patients, FEMS Immunol. Med. Microbiol., 37, 161, 10.1016/S0928-8244(03)00072-5 · doi:10.1016/s0928-8244(03)00072-5
  126. Rello, J., Krenn, C.-G., Locker, G., Pilger, E., Madl, C., Balica, L., Dugernier, T., Laterre, P.-F., Spapen, H., and Depuydt, P. (2017). A Randomized Placebo-Controlled Phase II Study of a Pseudomonas Vaccine in Ventilated ICU Patients. Crit. Care, 21. · DOI
  127. Adlbrecht, C., Wurm, R., Depuydt, P., Spapen, H., Lorente, J.A., Staudinger, T., Creteur, J., Zauner, C., Meier-Hellmann, A., and Eller, P. (2020). Efficacy, Immunogenicity, and Safety of IC43 Recombinant Pseudomonas aeruginosa Vaccine in Mechanically Ventilated Intensive Care Patients-a Randomized Clinical Trial. Crit. Care, 24. · doi:10.1186/s13054-020-2792-z
  128. Larbig, 2001, Safety and Immunogenicity of an Intranasal Pseudomonas aeruginosa Hybrid Outer Membrane Protein F-I Vaccine in Human Volunteers, Vaccine, 19, 2291, 10.1016/S0264-410X(00)00550-8 · DOI
  129. Baumann, U., Göcke, K., Gewecke, B., Freihorst, J., and von Specht, B.U. (2007). Assessment of Pulmonary Antibodies with Induced Sputum and Bronchoalveolar Lavage Induced by Nasal Vaccination against Pseudomonas aeruginosa: A Clinical Phase I/II Study. Respir. Res., 8. · DOI
  130. Baumann, 2003, Mucosal Vaccination with a Recombinant OprF-I Vaccine of Pseudomonas aeruginosa in Healthy Volunteers: Comparison of a Systemic vs. a Mucosal Booster Schedule, FEMS Immunol. Med. Microbiol., 37, 167, 10.1016/S0928-8244(03)00094-4 · DOI
  131. Gonzaga, Z.J.C., Merakou, C., DiGiandomenico, A., Priebe, G.P., and Rehm, B.H.A. (2021). A Pseudomonas aeruginosa-Derived Particulate Vaccine Protects against P. aeruginosa Infection. Vaccines, 9. · DOI
  132. Gonzaga, 2022, Intranasal Delivery of Antigen-Coated Polymer Particles Protects against Pseudomonas aeruginosa Infection, ACS Infect. Dis., 8, 744, 10.1021/acsinfecdis.1c00434 · DOI
  133. Shaikh, M.O.F., Schaefers, M.M., Merakou, C., DiBlasi, M., Bonney, S., Liao, T., Zurakowski, D., Kehl, M., Tabor, D.E., and DiGiandomenico, A. (2022). Multicomponent Pseudomonas aeruginosa Vaccines Eliciting Th17 Cells and Functional Antibody Responses Confer Enhanced Protection against Experimental Acute Pneumonia in Mice. Infect. Immun., 90. · DOI
  134. Sabzehali, F., Goudarzi, H., Goudarzi, M., Chirani, A.S., and Izad, M.H.Y. (2022). Immunopotentiating properties of chimeric OprF-OprI-PopB protein against Pseudomonas aeruginosa PAO1 in the infected burned rat model. Iran. J. Basic. Med. Sci., 25. · doi:10.1016/j.imu.2021.100673
  135. Wu, W., Huang, J., Duan, B., Traficante, D.C., Hong, H., Risech, M., Lory, S., and Priebe, G.P. (2012). Th17-Stimulating Protein Vaccines Confer Protection against Pseudomonas aeruginosa Pneumonia. Am. J. Respir. Crit. Care Med., 186. · DOI
  136. Gao, 2017, Vaccination with a Recombinant OprL Fragment Induces a Th17 Response and Confers Serotype-Independent Protection against Pseudomonas aeruginosa Infection in Mice, Clin. Immunol., 183, 354, 10.1016/j.clim.2017.09.022 · DOI
  137. Liu, C., Pan, X., Xia, B., Chen, F., Jin, Y., Bai, F., Priebe, G., Cheng, Z., Jin, S., and Wu, W. (2018). Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous Pseudomonas aeruginosa Strains Based on Expression Profiling of Outer Membrane Proteins During Infection. Front. Immunol., 9. · DOI
  138. Baker, 2019, Intradermal Vaccination with a Pseudomonas aeruginosa Vaccine Adjuvanted with a Mutant Bacterial ADP-Ribosylating Enterotoxin Protects against Acute Pneumonia, Vaccine, 37, 808, 10.1016/j.vaccine.2018.12.053 · DOI
  139. Tian, J., Gong, Q., Zhu, S., and Li, Y. (2023). Extracellular Polysaccharide of Lactobacillus Plantarum Enhance Immune Efficacy of oprH Gene Recombinant Subunit Vaccine from Pseudomonas aeruginosa. J. Vet. Med. Sci., 85. · DOI
  140. Golpasha, 2015, Immunization with 3-Oxododecanoyl-L-Homoserine Lactone-r-PcrV Conjugate Enhances Survival of Mice against Lethal Burn Infections Caused by Pseudomonas aeruginosa, Bosn. J. Basic. Med. Sci., 15, 15
  141. Asadi Karam, M.R., Badmasti, F., Ahmadi, K., and Habibi, M. (2022). Vaccination of Mice with Hybrid Protein Containing Exotoxin S and PcrV with Adjuvants Alum and MPL Protects Pseudomonas aeruginosa Infections. Sci. Rep., 12. · DOI
  142. Fakoor, 2020, Protective Efficacy of the OprF/OprI/PcrV Recombinant Chimeric Protein Against Pseudomonas aeruginosa in the Burned BALB/c Mouse Model, Infect. Drug Resist., 13, 1651, 10.2147/IDR.S244081 · DOI
  143. Kalantari, 2024, Development of a Multi-Epitope Vaccine Candidate against Pseudomonas aeruginosa Causing Urinary Tract Infection and Evaluation of Its Immunoreactivity in a Rabbit Model, J. Biomol. Struct. Dyn., 42, 6212, 10.1080/07391102.2023.2239915 · DOI
  144. Sawa, 1999, Active and Passive Immunization with the Pseudomonas V Antigen Protects against Type III Intoxication and Lung Injury, Nat. Med., 5, 392, 10.1038/7391 · DOI · Paper page
  145. Yang, F., Gu, J., Yang, L., Gao, C., Jing, H., Wang, Y., Zeng, H., Zou, Q., Lv, F., and Zhang, J. (2017). Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models. Sci. Rep., 7. · DOI
  146. Naito, 2018, The Protective Effects of Nasal PcrV-CpG Oligonucleotide Vaccination against Pseudomonas aeruginosa Pneumonia, Microbiol. Immunol., 62, 774, 10.1111/1348-0421.12658 · DOI
  147. Wan, C., Zhang, J., Zhao, L., Cheng, X., Gao, C., Wang, Y., Xu, W., Zou, Q., and Gu, J. (2019). Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against Pseudomonas aeruginosa. Front. Immunol., 10. · DOI
  148. Howlader, D.R., Mandal, R.S., Lu, T., Maiti, S., Dietz, Z.K., Das, S., Whittier, S.K., Nagel, A.C., Biswas, S., and Varisco, D.J. (2024). Development of a nano-emulsion based multivalent protein subunit vaccine against Pseudomonas aeruginosa. Front. Immunol., 15. · DOI
  149. Das, S., Howlader, D.R., Zheng, Q., Ratnakaram, S.S.K., Whittier, S.K., Lu, T., Keith, J.D., Picking, W.D., Birket, S.E., and Picking, W.L. (2020). Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by Pseudomonas aeruginosa. Front. Immunol., 11. · DOI
  150. Howlader, D.R., Das, S., Lu, T., Hu, G., Varisco, D.J., Dietz, Z.K., Walton, S.P., Ratnakaram, S.S.K., Gardner, F.M., and Ernst, R.K. (2021). Effect of Two Unique Nanoparticle Formulations on the Efficacy of a Broadly Protective Vaccine Against Pseudomonas aeruginosa. Front. Pharmacol., 12. · doi:10.3389/fphar.2021.706157
  151. Howlader, D.R., Das, S., Lu, T., Mandal, R.S., Hu, G., Varisco, D.J., Dietz, Z.K., Ratnakaram, S.S.K., Ernst, R.K., and Picking, W.D. (2023). A Protein Subunit Vaccine Elicits a Balanced Immune Response That Protects against Pseudomonas Pulmonary Infection. NPJ Vaccines, 8. · doi:10.1038/s41541-023-00618-w
  152. Wang, Y., Cheng, X., Wan, C., Wei, J., Gao, C., Zhang, Y., Zeng, H., Peng, L., Luo, P., and Lu, D. (2021). Development of a Chimeric Vaccine Against Pseudomonas aeruginosa Based on the Th17-Stimulating Epitopes of PcrV and AmpC. Front. Immunol., 11. · DOI
  153. Ou, Y., Wang, Y., Yu, T., Cui, Z., Chen, X., Zhang, W., Zou, Q., Gu, J., and Zuo, Q. (2022). Intranasal Vaccination with rePcrV Protects against Pseudomonas aeruginosa and Generates Lung Tissue-Resident Memory T Cells. J. Immunol. Res., 2022. · DOI
  154. Li, Y., Pu, R., Zhang, Y., Zhang, Y., Wei, Y., Zeng, S., Gao, C., Wang, Y., Yin, D., and Zhang, Y. (2023). Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free Pseudomonas aeruginosa vaccine. Front. Immunol., 14. · DOI
  155. Inoue, K., Kinoshita, M., Muranishi, K., Ohara, J., Sudo, K., Kawaguchi, K., Shimizu, M., Naito, Y., Moriyama, K., and Sawa, T. (2023). Effect of a Novel Trivalent Vaccine Formulation against Acute Lung Injury Caused by Pseudomonas aeruginosa. Vaccines, 11. · doi:10.3390/vaccines11061088
  156. Forslund, 2003, PcrH of Pseudomonas aeruginosa Is Essential for Secretion and Assembly of the Type III Translocon, J. Infect. Dis., 188, 1909, 10.1086/379898 · DOI
  157. Schaefers, M.M., Duan, B., Mizrahi, B., Lu, R., Reznor, G., Kohane, D.S., and Priebe, G.P. (2018). PLGA-Encapsulation of the Pseudomonas aeruginosa PopB Vaccine Antigen Improves Th17 Responses and Confers Protection against Experimental Acute Pneumonia. Vaccine, 36. · DOI
  158. Cheng, X., Chen, Z., Gao, C., Zhang, Y., Yang, L., Wan, J., Wei, Y., Zeng, S., Zhang, Y., and Zhang, Y. (2023). Structural and Biological Insights into Outer Membrane Protein Lipotoxin F of Pseudomonas aeruginosa: Implications for Vaccine Application. Int. J. Biol. Macromol., 253. · DOI
  159. Askarian, F., Tsai, C.-M., Cordara, G., Zurich, R.H., Bjånes, E., Golten, O., Sørensen, H.V., Kousha, A., Meier, A., and Chikwati, E. (2023). Immunization with Lytic Polysaccharide Monooxygenase CbpD Induces Protective Immunity against Pseudomonas aeruginosa Pneumonia. Proc. Natl. Acad. Sci. USA, 120. · DOI
  160. Banadkoki, 2016, Protective Effect of Pilin Protein with Alum+naloxone Adjuvant against Acute Pulmonary Pseudomonas aeruginosa Infection, Biologicals, 44, 367, 10.1016/j.biologicals.2016.06.009 · DOI
  161. Gao, 2022, A Novel Structurally Identified Epitope Delivered by Macrophage Membrane-Coated PLGA Nanoparticles Elicits Protection against Pseudomonas aeruginosa, J. Nanobiotechnol., 20, 1, 10.1186/s12951-022-01725-x · doi:10.1186/s12951-022-01725-x
  162. Kao, 2007, Animal Protection and Structural Studies of a Consensus Sequence VaccineTargeting the Receptor Binding Domain of the Type IV Pilus of Pseudomonas aeruginosa, J. Mol. Biol., 374, 426, 10.1016/j.jmb.2007.09.032 · DOI
  163. Kao, 2009, Advantages of a Synthetic Peptide Immunogen Over a Protein Immunogen in the Development of an Anti-Pilus Vaccine for Pseudomonas aeruginosa, Chem. Biol. Drug Des., 74, 33, 10.1111/j.1747-0285.2009.00825.x · DOI
  164. Korpi, 2016, Flagellin and Pilin Immunization against Multi-Drug Resistant Pseudomonas aeruginosa Protects Mice in the Burn Wound Sepsis Model, Immunol. Lett., 176, 8, 10.1016/j.imlet.2016.04.002 · DOI
  165. Mousavi, 2016, Passive immunization against Pseudomonas aeruginosa recombinant PilA in a murine burn wound model, Microb Pathog., 101, 83, 10.1016/j.micpath.2016.10.027 · DOI
  166. Laghaei, 2016, Immunogenicity and Protective Efficacy of Pseudomonas aeruginosa Type a and b Flagellin Vaccines in a Burned Mouse Model, Mol. Immunol., 74, 71, 10.1016/j.molimm.2016.04.008 · DOI
  167. Saffari, 2017, Antibodies Raised against Divalent Type b Flagellin and Pilin Provide Effective Immunotherapy against Pseudomonas aeruginosa Infection of Mice with Burn Wounds, Biologicals, 45, 20, 10.1016/j.biologicals.2016.10.007 · doi:10.1016/j.biologicals.2016.10.007
  168. Nikokar, 2018, Evaluation of the Immune Responses Following Co-Administration of PilQ and Type b-Flagellin from Pseudomonas aeruginosa in the Burn Mouse Model, Microb. Pathog., 123, 426, 10.1016/j.micpath.2018.07.042 · DOI
  169. Hashemi, F.B., Behrouz, B., Irajian, G., Laghaei, P., Korpi, F., and Fatemi, M.J. (2020). A Trivalent Vaccine Consisting of “Flagellin A+B and Pilin” Protects against Pseudomonas aeruginosa Infection in a Murine Burn Model. Microb. Pathog., 138. · doi:10.1016/j.micpath.2019.103697
  170. Heurtault, 2009, Design of a Liposomal Candidate Vaccine Against Pseudomonas aeruginosa and Its Evaluation in Triggering Systemic and Lung Mucosal Immunity, Pharm. Res., 26, 276, 10.1007/s11095-008-9724-y · DOI
  171. Gholami, 2017, Immunogenicity of a Fusion Protein Containing PilQ and Disulphide Turn Region of PilA from Pseudomonas aeruginosa in Mice, Lett. Appl. Microbiol., 65, 439, 10.1111/lam.12796 · DOI
  172. Ahmadbeigi, 2020, Immunopotentiation of the Engineered Low-Molecular-Weight Pilin Targeting Pseudomonas aeruginosa: A Combination of Immunoinformatics Investigation and Active Immunization, Mol. Immunol., 124, 70, 10.1016/j.molimm.2020.05.009 · DOI
  173. Jazi, M.A., Chirani, A.S., Hajikhani, B., Ebrahimipour, G., and Goudarzi, M. (2023). Unraveling the Immunopotentiation of P. aeruginosa PAPI-1 Encoded Pilin: From Immunoinformatics Survey to Active Immunization. Int. Immunopharmacol., 125. · doi:10.1016/j.intimp.2023.111197
  174. Jazi, M.A., Hajikhani, B., Goudarzi, M., and Ebrahimipour, G. (2024). Exploiting Immunopotential PAPI-1 Encoded Type IVb Major Pilin Targeting Pseudomonas aeruginosa. Heliyon, 10. · DOI
  175. Ahmadi, 2017, Bivalent Flagellin Immunotherapy Protects Mice against Pseudomonas aeruginosa Infections in Both Acute Pneumonia and Burn Wound Models, Biologicals, 46, 29, 10.1016/j.biologicals.2016.12.005 · DOI
  176. Holder, 1986, Experimental Studies of the Pathogenesis of Infections Due to Pseudomonas aeruginosa: Immunization Using Divalent Flagella Preparations, J. Trauma., 26, 118, 10.1097/00005373-198602000-00003 · doi:10.1097/00005373-198602000-00003
  177. Holder, 1982, Flagellar Preparations from Pseudomonas aeruginosa: Animal Protection Studies, Infect. Immun., 35, 276, 10.1128/iai.35.1.276-280.1982 · doi:10.1128/iai.35.1.276-280.1982
  178. Montie, 1982, Flagellar Preparations from Pseudomonas aeruginosa: Isolation and Characterization, Infect. Immun., 35, 281, 10.1128/iai.35.1.281-288.1982 · doi:10.1128/iai.35.1.281-288.1982
  179. Faezi, 2017, Preparation of Pseudomonas aeruginosa Alginate-Flagellin Immunoconjugate, Biologicals, 47, 11, 10.1016/j.biologicals.2017.04.001 · DOI
  180. Weimer, 2009, A Fusion Protein Vaccine Containing OprF Epitope 8, OprI, and Type A and B Flagellins Promotes Enhanced Clearance of Nonmucoid Pseudomonas aeruginosa, Infect. Immun., 77, 2356, 10.1128/IAI.00054-09 · DOI
  181. Llosa, 2010, Evaluation of Flagella and Flagellin of Pseudomonas aeruginosa as Vaccines, Infect. Immun., 78, 746, 10.1128/IAI.00806-09 · DOI
  182. Llosa, 2011, Efficacy of a Conjugate Vaccine Containing Polymannuronic Acid and Flagellin against Experimental Pseudomonas aeruginosa Lung Infection in Mice, Infect. Immun., 79, 3455, 10.1128/IAI.00157-11 · doi:10.1128/iai.00157-11
  183. Behrouz, B., Hashemi, F.B., Fatemi, M.J., Naghavi, S., Irajian, G., Halabian, R., and Imani Fooladi, A.A. (2017). Immunization with Bivalent Flagellin Protects Mice against Fatal Pseudomonas aeruginosa Pneumonia. J. Immunol. Res., 2017. · DOI
  184. Korpi, F., Irajian, G., Forouhi, F., and Mohammadian, T. (2023). A Chimeric Vaccine Targeting Pseudomonas aeruginosa Virulence Factors Protects Mice against Lethal Infection. Microb. Pathog., 178. · DOI
  185. Wan, 2021, Flagella Hook Protein FlgE Is a Novel Vaccine Candidate of Pseudomonas aeruginosa Identified by a Genomic Approach, Vaccine, 39, 2386, 10.1016/j.vaccine.2021.03.051 · DOI
  186. Wei, 2023, Recombinant Pseudomonas aeruginosa Flagellin Delivered Using Ferritin Nanoparticles Provides Enhanced Cross-Protection against Lung Infection in Mice, Mol. Immunol., 163, 235, 10.1016/j.molimm.2023.10.005 · DOI
  187. Choi, M., Shridhar, S., Fox, H., Luo, K., Amin, M.N., Tennant, S.M., Simon, R., and Cross, A.S. (2024). The O-Glycan Is Essential for the Induction of Protective Antibodies against Lethal Infection by Flagella A-Bearing Pseudomonas aeruginosa. Infect. Immun., 92. · DOI
  188. Pfeiffer, 1995, Parenteral Application of a Pseudomonas aeruginosa Flagella Vaccine Elicits Specific Anti-Flagella Antibodies in the Airways of Healthy Individuals, Am. J. Respir. Crit. Care Med., 151, 983
  189. Crowe, 1991, The First Clinical Trial of Immuno’s Experimental Pseudomonas aeruginosa Flagellar Vaccines, Antibiot Chemother, 44, 143, 10.1159/000420309 · doi:10.1159/000420309
  190. Meisner, 2007, A Double-Blind Randomized Placebo-Controlled Phase III Study of a Pseudomonas aeruginosa Flagella Vaccine in Cystic Fibrosis Patients, Proc. Natl. Acad. Sci. USA, 104, 11020, 10.1073/pnas.0702403104 · DOI · Paper page
  191. Sokol, 2000, Immunization with a Pseudomonas aeruginosa Elastase Peptide Reduces Severity of Experimental Lung Infections Due to P. aeruginosa or Burkholderia cepacia, J. Infect. Dis., 181, 1682, 10.1086/315470 · doi:10.1086/315470
  192. Kawamoto, S., Shibano, Y., Fukushima, J., Ishii, N., Morihara, K., and Okuda, K. (1993). Site-Directed Mutagenesis of Glu-141 and His-223 in Pseudomonas aeruginosa Elastase: Catalytic Activity, Processing, and Protective Activity of the Elastase against Pseudomonas Infection. Infect. Immun., 61. · doi:10.1128/iai.61.4.1400-1405.1993
  193. Thomas, 2000, Catalase Immunization from Pseudomonas aeruginosa Enhances Bacterial Clearance in the Rat Lung, Vaccine, 19, 348, 10.1016/S0264-410X(00)00146-8 · doi:10.1016/s0264-410x(00)00146-8
  194. Thomas, 2009, Immune Response Mechanisms against Pseudomonas aeruginosa Associated with Mucosal Immunization with Protein Antigens in a Rat Model of Acute Lung Infection, Vaccine, 27, 3324, 10.1016/j.vaccine.2009.01.085 · doi:10.1016/j.vaccine.2009.01.085
  195. Sen-Kilic, E., Blackwood, C.B., Boehm, D.T., Witt, W.T., Malkowski, A.C., Bevere, J.R., Wong, T.Y., Hall, J.M., Bradford, S.D., and Varney, M.E. (2019). Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice from Pseudomonas aeruginosa Acute Murine Pneumonia. Front. Immunol., 10. · DOI
  196. Michalska, M., and Wolf, P. (2015). Pseudomonas Exotoxin A: Optimized by Evolution for Effective Killing. Front. Microbiol., 6. · DOI · Paper page
  197. Lukac, 1988, Toxoid of Pseudomonas aeruginosa Exotoxin A Generated by Deletion of an Active-Site Residue, Infect. Immun., 56, 3095, 10.1128/iai.56.12.3095-3098.1988 · doi:10.1128/iai.56.12.3095-3098.1988
  198. Chen, 1999, A Nontoxic Pseudomonas Exotoxin A Induces Active Immunity and Passive Protective Antibody against Pseudomonas Exotoxin a Intoxication, J. Biomed. Sci., 6, 357
  199. Hsieh, 2005, Intranasal Immunization Strategy To Impede Pilin-Mediated Binding of Pseudomonas aeruginosa to Airway Epithelial Cells, Infect. Immun., 73, 7705, 10.1128/IAI.73.11.7705-7717.2005 · doi:10.1128/iai.73.11.7705-7717.2005
  200. Farajnia, 2015, Protective Efficacy of Recombinant Exotoxin A—Flagellin Fusion Protein against Pseudomonas aeruginosa Infection, Can. J. Microbiol., 61, 60, 10.1139/cjm-2014-0501 · DOI · Paper page

200 of 229 shown

Cited by

See all 33

Metadata

Authors
Santamarina-Fernández, R., Fuentes-Valverde, V., Silva-Rodríguez, A., García, P., Moscoso, M., & Bou, G.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2025-02-25
Volume
26
Issue
5
Pages
2012
ISSN
1422-0067
Cited by
33
References
3
Language
en
Funders
  • SERGAS-Galician Healthcare Service (CB21/13/00055, PI18/00501, PI21/00704, IN606A-2019/012)
  • CIBERINFEC (CB21/13/00055, PI18/00501, PI21/00704, IN606A-2019/012)
  • Ministry of Economy and Competitiveness (CB21/13/00055, PI18/00501, PI21/00704, IN606A-2019/012)
  • Conselleria de Cultura (CB21/13/00055, PI18/00501, PI21/00704, IN606A-2019/012)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.